MapLight Therapeutics (MPLT) Total Liabilities (2024 - 2026)
MapLight Therapeutics (MPLT) posted Total Liabilities of $21.1 million for Q4 2025, down 10.82% sequentially from $23.7 million in Q3 2025, and down 2.67% YoY from $21.7 million in Q4 2024.
MapLight Therapeutics (MPLT) Total Liabilities (2024 - 2026) Analysis & Trends
MapLight Therapeutics has reported Total Liabilities for 2 years, with the latest figure at $21.1 million in Q4 2025.
- Quarterly Total Liabilities fell 2.67% year-over-year to $21.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21.1 million (down 2.67% YoY) and the FY2025 annual result came in at $21.1 million, down 2.67% from the prior year.
- Total Liabilities slipped to $21.1 million in Q4 2025 per MPLT's latest filing, from $23.7 million in the prior quarter.
- Over five years, Total Liabilities peaked at $23.7 million in Q3 2025 and troughed at $21.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | MapLight Therapeutics | 533.88 Mn | 533.88 Mn | - | 20.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.05 Mn |
| Dec 31, 2025 | 21.14 Mn |
| Sep 30, 2025 | 23.71 Mn |
| Dec 31, 2024 | 21.72 Mn |